A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
8actual
Sites
15
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-06 | actual | When the study began enrolling |
| Primary completion | 2026-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-31 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non Small Cell Lung
- Carcinoma, Pancreatic Ductal
- Malignant Melanoma
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
- Drug: PF-08046037 — also filed as SGN-PDL1iT
- Drug: sasanlimab — also filed as PF-06801591
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with laboratory abnormalities
measured Through 30-37 days after the last study treatment, up to approximately 2 years
Number of dose modifications due to AEs
measured Through end of treatment up to approximately 2 years
Number of participants with dose-limiting toxicities (DLTs)
measured Up to 21 days
Number of participants with DLTs by dose level
measured Up to 21 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed